Enzon and Santaris to develop RNA-based cancer therapeutics
USA-based Enzon Pharmaceuticals and Danish drugmaker Santaris Pharma AS say that they have entered into a co-development and commercialization accord, which could earn the latter $200.0 million.
Under the terms of the agreement, they will focus on the development of two RNA antagonists based on the latter's Locked Nucleic Acid technology, namely the HIF-1a antagonist (SPC2968) and the Survivin antagonist (SPC3042). Enzon will make an $8.0 million upfront payment in return for an exclusive license to develop the two compounds, as well as six other agents from the Danish firm's portfolio in the USA and other territories outside Europe. Additionally the New Jersey-headquartered company is required to provide a further $3.0 million on the successful identification of pre-defined developmental milestones. Full financial terms of the deal were not provided.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze